Loading data for JUNS — first visit, this takes a few seconds.

알림

Jupiter Neurosciences Inc... (JUNS)

NasdaqCM: JUNS · 실시간 가격 · USD

4.18

-0.71 (-14.52%)

종가 기준: Aug 21, 2026, 8:00 PM

6.12

-1.29%

애프터마켓: 7:59 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-14.52% (1D)

데이터 없음

매수호가	5.33
시가총액	4.77M
매출 (ttm)	64.69K
순이익 (ttm)	-9.2M
	n/a
	-18.7
	n/a
	103.33
P/B (ttm)	-1.08
P/S (ttm)	73.80
실적 발표일	n/a

매도호가	5.35
거래량	204,251
평균 거래량 (20일)	991,079
시가	5.15
전일 종가	4.89
일중 범위	4.10 - 5.15
52주 범위	4.10 - 138.00
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

JUNS 소개

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Dec 3, 2024

직원 수 5

상장 거래소 NasdaqCM

티커 JUNS

웹사이트 https://jupiterneurosciences.com

전체 기업 정보

재무 실적

2025년 Jupiter Neurosciences의 매출은 21.8K로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -8.64M로, 254.35% 증가했습니다.

재무제표

어닝 서프라이즈

Jupiter Neurosciences가 Nov 14, 2025에 분기 실적을 발표했습니다:

매출 $18.65K 예상치 하회 $0, 및 Infinity% 전년 대비 성장.
EPS -5.25 예상치 상회 0.75, 및 -250.00% 전년 대비 감소.

뉴스

1주 전 · MT Newswires

US Equity Indexes Rise Despite Surging Bond Yields as US Nears Tariff Deal With Canada

US equity indexes rose markedly on Friday, even as bond yields continued to rise after Canada's trad

1주 전 · MT Newswires

US Equity Indexes Rise Despite Surging Bond Yields

US equity indexes rose markedly ahead of the close on Friday after a sharp selloff in the previous s

1주 전 · Exec Edge

Real Parkinson’s Disease Hope from Jupiter Neurosciences

By Mike Sheikh Parkinson’s Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The mar...

1개월 전 · IPO-Edge.com

Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva

Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Sil...

1개월 전 · InvestorsHub

Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS)

The exclusive U. S. licensing deal adds a second clinical-stage CNS asset to Jupiter Neurosciences’ pipeline, expanding its development strategy beyond its lead Parkinson’s disease program.

2 페이지 중 1

Jupiter Neurosciences Inc... (JUNS)